0000899243-21-028984.txt : 20210720 0000899243-21-028984.hdr.sgml : 20210720 20210720161727 ACCESSION NUMBER: 0000899243-21-028984 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210713 FILED AS OF DATE: 20210720 DATE AS OF CHANGE: 20210720 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BINGHAM KATE CENTRAL INDEX KEY: 0001185040 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38916 FILM NUMBER: 211101371 MAIL ADDRESS: STREET 1: 1365 MAIN STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BICYCLE THERAPEUTICS plc CENTRAL INDEX KEY: 0001761612 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 BUSINESS ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT BUSINESS PHONE: 011441223261503 MAIL ADDRESS: STREET 1: B900 BABRAHAM RESEARCH CAMPUS CITY: CAMBRIDGE STATE: X0 ZIP: CB22 3AT FORMER COMPANY: FORMER CONFORMED NAME: BICYCLE THERAPEUTICS Ltd DATE OF NAME CHANGE: 20181212 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2021-07-13 2021-07-15 1 0001761612 BICYCLE THERAPEUTICS plc BCYC 0001185040 BINGHAM KATE C/O BICYCLE THERAPEUTICS B900, BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT UNITED KINGDOM 1 0 0 0 Ordinary Shares 2021-07-13 4 S 0 588 33.50 D 1875049 I By SV Life Sciences Fund V, L.P. Ordinary Shares 2021-07-14 4 S 0 43378 34.0076 D 1831671 I By SV Life Sciences Fund V, L.P. Ordinary Shares 2021-07-13 4 S 0 12 33.50 D 39625 I By SV Life Sciences Fund V Strategic Partners, L.P. Ordinary Shares 2021-07-14 4 S 0 917 34.0076 D 38708 I By SV Life Sciences Fund V Strategic Partners, L.P. These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein. These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein. The original Form 4 filed on July 15, 2021 is amended by this Form 4 amendment to reflect Ms. Bingham's resignation from the Board of Directors effective as of the Annual Meeting held on June 28, 2021. As a result of her resignation, Ms. Bingham is no longer subject to Section 16 reporting requirements. /s/ Kate Bingham 2021-07-20